Life Sciences

Why In-House Experience Matters
Our experience as former biotech in-house counsel, venture capital senior managers and pharmaceutical contract specialists creates an exceptional service experience for our clients.

Overview

On June 1, 2025, Crowell & Moring LLP and Faber Daeufer & Itrato combined to establish Crowell Life Sciences. This team, distinguished by deep industry and government experience, provides companies, academic research institutions, and investors in the life sciences ecosystem with integrated and industry-leading transactional, regulatory, intellectual property, and litigation counsel.   

Crowell Life Sciences brings together Faber’s leading life sciences-focused venture finance, R&D transactional, and complex licensing and development agreements practice, with Crowell’s strengths in health care regulatory, government contracting, international trade, data privacy, patent prosecution, and health care and IP litigation, positioning the team to provide clients with solution-oriented guidance in a dynamic business environment. 

Crowell Life Sciences is uniquely comprised of former in-house lawyers and business executives in biopharma, private fund professionals, and contract specialists from pharmaceutical companies and contract research organizations.  

The team delivers pragmatic corporate and transactional counsel to life sciences companies from start-up through commercialization, to investment firms, to academic research institutions, and to NGOs involved in the discovery, development, manufacture, and commercialization of novel therapeutics, devices, and research tools aided by emerging AI and in silico technologies. 

As life sciences companies and investors advance mission-critical strategies at a time of rapid change and economic uncertainty, Crowell is well-positioned to provide valuable industry and government insight.

Whether it’s cross-border engagement with investors and business and scientific partners, U.S. and EU regulatory compliance, new tariff regimes, supply chain disruption or export controls, Crowell Life Sciences supports clients as they navigate increased complexity in designing R&D and go-to-market strategies along with a myriad of IP and data protection challenges, including global patent prosecution. Across the lifecycle of life sciences businesses, clients benefit from the well-integrated business, legal, and government experience of Crowell Life Sciences.

Industry Know How

Representative Matters

Tasca Therapeutics Corp.

Series A Financing

Tasca Therapeutics launches with $52 million in Series A financing co-led by Regeneron Ventures and Cure Ventures, and with participation by Invus Group.

2024

EvolveImmune Therapeutics, Inc. + AbbVie

Collaboration and License Agreement

EvolveImmune Therapeutics in a collaboration and option-to-license agreement with AbbVie to develop multispecific biologics for multiple targets in oncology leveraging EvolveImmune’s T-cell engager platform, with an upfront payment of $65 million, up to $1.4 billion in option fees and milestones, as well as tiered royalty payments on net sales.

2024

Ananda Scientific, Inc.

Investigator-Initiated Clinical Trial Agreement

Counsel to Ananda Scientific in collaboration with Yale School of Medicine to conduct investigator initiated clinical trial evaluating Nantheia™ ATL5 for use in treating co-occurring opioid use disorder (OUD) and chronic pain. The study will be led by Principal Investigator Joao P. De Aquino, M.D.

2024

GV Management Company, LLC

PeopleOne Health Series B Financing

Representation of GV Management Company as lead in PeopleOne Health’s $32.3M Series B Financing.

2024

Novo Nordisk A/S

Asset Purchase Agreement and Grant-Back License Agreement

Counsel to Novo Nordisk in acquisition of 2seventy’s Hemophilia A program and rights to MegaTAL in vivo gene editing technology.

2024

NextPoint Therapeutics, Inc.

Series B Financing - Extension

NextPoint Therapeutics raises $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi. NextPoint subsequently raises $42.5M in an extension to its Series B led by Catalio Capital Management, bringing the total raised to $122.5M. Additional investors in the round include MPM BioImpact, Invus, Sixty Degree Capital, Binney Street Capital, and Arkin Bio-Capital.

2024

GV Management Company, LLC

Series B Financing

Representation of GV Management Company, as lead, and a16z Bio + in Santa Ana Bio’s $125M Series B Financing. Other investors included TPG, Access Biotechnology, and RTW.

2024

Claris Biotherapeutics, Inc.

Series A-3 preferred stock financing

Claris Bio closes latest venture round to bring total financing to roughly $60 million, accelerating its late-stage clinical development of a novel therapeutic agent for neurotrophic keratopathy. Investors include Novo Holdings A/S, RA Capital, Mass General Brigham Ventures, and Janus Henderson Investors.

2024

GV Management Company, LLC

Chroma Medicine Series B Financing

Representation of GV, as lead, ARCH Venture Partners and DCVC in Chroma Medicine’s $135M Series B Financing.

2023

Praeventix, Inc.

Series Seed Financing

Private Investment from Tellus BioVentures.

2022

Paragon Therapeutics, Inc.

Discovery and Option Agreement

Option for exclusive development and commercial rights to a suite of Paragon’s top-tier antibodies specifically engineered to target some of the largest and highest unmet needs in inflammatory and immunological conditions.

2022

Epalex Corporation

Series A-3 Financing

Series A-3 preferred equity financing to continue advancing Epalex’s two clinical-stage development programs.

2022

Professionals